Akums Delivers Strong Q3 FY26 Results: 14.8% Revenue Growth and 21% EBITDA Rise

Akums Drugs & Pharmaceuticals Ltd., India’s largest contract drug manufacturer, has reported strong Q3 FY26 financial results. The company posted 14.8% revenue growth and 21% adjusted EBITDA growth year-on-year, demonstrating robust execution across its business segments.

Q3 FY26 Financial Highlights

The Q3 FY26 results reflect continued momentum in Akums’ core business lines. Key highlights from the quarter include:

• Revenue growth of 14.8% year-on-year
• Adjusted EBITDA growth of 21% year-on-year
• Strong performance across domestic and export markets
• Continued investment in manufacturing capacity and EU-compliant facilities

Business Performance and Outlook

Akums has been expanding its pharmaceutical manufacturing footprint with a focus on quality compliance and regulatory approvals. The Q3 FY26 results underline the company’s strong fundamentals in a competitive sector.

The company’s growth is driven by demand from domestic formulation companies, generics exports, and its nutraceuticals division. Management has reiterated its commitment to margin improvement through operational efficiencies.

About Akums Drugs and Pharmaceuticals

Akums Drugs & Pharmaceuticals Ltd. is India’s largest contract development and manufacturing organisation (CDMO). Listed on Indian stock exchanges, the company serves hundreds of pharmaceutical brands across multiple therapeutic categories.

Also read: Finance & Markets News India | Business News India